Norris Medicines Limited (BOM:524414)
India
· Delayed Price · Currency is INR 15.00
+0.71 (4.97%)
At close: Mar 10, 2026
Norris Medicines Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 94.44 | 58.2 | 56.36 | 83.59 | 94.38 | 122.51 | Upgrade
|
| Revenue Growth (YoY) | 105.90% | 3.28% | -32.58% | -11.44% | -22.96% | 56.19% | Upgrade
|
| Cost of Revenue | 56.86 | 35.08 | 26.99 | 35.23 | 57.25 | 89.07 | Upgrade
|
| Gross Profit | 37.58 | 23.12 | 29.36 | 48.36 | 37.13 | 33.44 | Upgrade
|
| Selling, General & Admin | 18.57 | 14.13 | 18.21 | 22.98 | 23.38 | 31 | Upgrade
|
| Other Operating Expenses | 14.31 | 11.2 | 12.94 | 16.13 | 14.39 | 19.85 | Upgrade
|
| Operating Expenses | 37.96 | 30.7 | 36.86 | 45.4 | 44.33 | 57.53 | Upgrade
|
| Operating Income | -0.37 | -7.58 | -7.5 | 2.95 | -7.2 | -24.09 | Upgrade
|
| Interest Expense | -4.72 | -4.21 | -3.66 | -14.89 | -14.73 | -16.2 | Upgrade
|
| Interest & Investment Income | 0.18 | 0.18 | 0.18 | 0.12 | 0.12 | 0.13 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | 0.01 | 0.04 | - | 0.05 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.1 | -0.19 | -0.04 | -0.12 | -0.09 | 0.23 | Upgrade
|
| EBT Excluding Unusual Items | -5 | -11.78 | -10.98 | -11.93 | -21.85 | -39.93 | Upgrade
|
| Pretax Income | -5 | -11.78 | -10.98 | -11.93 | -21.85 | -39.93 | Upgrade
|
| Income Tax Expense | 0.59 | 0.59 | 0.89 | 5.56 | 10.79 | 9.69 | Upgrade
|
| Net Income | -5.6 | -12.37 | -11.87 | -17.49 | -32.63 | -49.62 | Upgrade
|
| Net Income to Common | -5.6 | -12.37 | -11.87 | -17.49 | -32.63 | -49.62 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| EPS (Basic) | -0.55 | -1.24 | -1.19 | -1.75 | -3.26 | -4.96 | Upgrade
|
| EPS (Diluted) | -0.56 | -1.24 | -1.19 | -1.75 | -3.26 | -4.96 | Upgrade
|
| Free Cash Flow | - | 4.91 | 1.69 | 11.7 | -10.65 | 10.26 | Upgrade
|
| Free Cash Flow Per Share | - | 0.49 | 0.17 | 1.17 | -1.06 | 1.03 | Upgrade
|
| Gross Margin | 39.79% | 39.72% | 52.10% | 57.86% | 39.34% | 27.29% | Upgrade
|
| Operating Margin | -0.40% | -13.03% | -13.31% | 3.54% | -7.63% | -19.66% | Upgrade
|
| Profit Margin | -5.93% | -21.26% | -21.06% | -20.93% | -34.58% | -40.50% | Upgrade
|
| Free Cash Flow Margin | - | 8.44% | 2.99% | 13.99% | -11.28% | 8.37% | Upgrade
|
| EBITDA | 4.74 | -2.21 | -1.78 | 9.25 | -0.63 | -17.42 | Upgrade
|
| EBITDA Margin | 5.01% | -3.80% | -3.17% | 11.07% | -0.67% | -14.22% | Upgrade
|
| D&A For EBITDA | 5.11 | 5.37 | 5.71 | 6.3 | 6.57 | 6.67 | Upgrade
|
| EBIT | -0.37 | -7.58 | -7.5 | 2.95 | -7.2 | -24.09 | Upgrade
|
| EBIT Margin | -0.40% | -13.03% | -13.31% | 3.54% | -7.63% | -19.66% | Upgrade
|
| Revenue as Reported | 95.14 | 58.82 | 56.64 | 83.73 | 94.64 | 123.04 | Upgrade
|
| Advertising Expenses | - | 0.06 | - | -0.01 | 0.08 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.